on EUROMEDIS GROUPE (EPA:ALEMG)
Euromedis Laboratories: 2026 Half-Year Financial Results
Euromedis Laboratories' financial report for the first half of 2026 reveals an 11.6% increase in revenue, reaching €22.8 million. This growth is attributed to increased sales in France and abroad. Gross profit reached €7.8 million, a 36% increase compared to 2025, primarily due to improved margin management. Net income, including the sale of real estate, amounted to €3.9 million, compared to €0.1 million last year.
Furthermore, the company recorded a provision of €1.4 million related to a tax audit. Despite an anticipated impact on second-half cash flow, the company plans to continue its structural optimizations while navigating an uncertain economic climate.
The outlook for the remainder of 2026 is based on the continuation of the current momentum, although pressures on supply costs remain a challenge.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EUROMEDIS GROUPE news